Spruce Biosciences (SPRB) Cash from Investing Activities (2019 - 2026)

Spruce Biosciences (SPRB) has reported Cash from Investing Activities for 6 consecutive years, with -$10000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$10000.0; the TTM figure through Mar 2026 stood at -$10000.0 (changed N/A YoY), while the FY2023 annual figure was $55.8 million, up 135.43% from the prior year.
• Cash from Investing Activities eased to -$10000.0 in Q1 2026 per SPRB's latest filing, from $9.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $33.5 million in Q2 2022 and bottomed at -$16.9 million in Q3 2022.
• Historically, Cash from Investing Activities has averaged $8.8 million across 3 years, with a median of $10.5 million in 2023.
• On a YoY basis, Cash from Investing Activities climbed as much as 343.51% in 2022 and fell as far as 39326.32% in 2022.
• Spruce Biosciences' Cash from Investing Activities stood at $14.6 million in 2022, then slumped by 36.17% to $9.3 million in 2023, then sank by 100.11% to -$10000.0 in 2026.
• Business Quant data shows SPRB's Cash from Investing Activities at -$10000.0 in Q1 2026, $9.3 million in Q4 2023, and $14.0 million in Q3 2023.